The effect of A02131-1 [3-(5'-hydroxymethyl-2'-furyl)-l-benzyl thieno (3.2-c)pyrazolel, a cGMP-specific phosphodiesterase (PDE) inhibitor, on platelet function was investigated. The compound was found t o inhibit the aggregation of and adenosine triphosphate (ATP) release from human plateletrich plasma and washed platelets that were induced by aggregation inducing drugs such as arachidonic acid (AA), collagen, U46619, platelet-activating factor (PAF), adenosine diphosphate (ADP) and A23187, and the inhibitory effect was concentration-dependent. A02131-1 also disaggregated the preformed platelet aggregates induced by these inducers. Thromboxane B2 ( T X b ) formations caused by collagen, PAF, ADP, and A23187 were inhibited by A02131-1 at concentrations that did not affect the AA-induced formation of TXB2 and prostaglandin DZ (PGD2). A02131-1 suppressed both the generation of inositol 1.4.5-trisphosphate (IP,) and the in-LATELET-VESSEL wall interactions are well known P to be important in the development of thrombosis, myocardial infarction, stroke, and atherosclerosis.'~' Platelets are activated by diverse stimuli in vivo, including diseased arteries4 Activation of platelets may lead not only to thrombosis but also, perhaps because of the release of growth factors, to enduring ill effects such as smooth muscle proliferation, one of the hallmarks of atherosclerosis.' Mural thrombus formation can restrict the flow of blood to vital tissues or organs leading to peripheral, cerebral, or coronary ischemia. The developing thrombus may embolize with potentially lethal consequences. Thus, pharmacological modulation of platelet function is a clinically effective mean in the prevention of stroke, myocardial infarction, and vascular diseases.j. ' Platelet function in response to various agonists can be regulated by adenosine 3',5'-cyclic monophosphate (CAMP) and guanosine 3',5'-cyclic monophosphate (cGMP).~ The role of cGMP in platelet activation is not completely understood. Because many agonists, including collagen and thrombin, may increase cGMP level of platelet^,^,' it was originally thought that an increase would help platelet activation.'" However, subsequent studies show that cGMP may inhibit platelet function. Stimulation of adenylate cyclase by prosta- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1996 by The American Society of Hematology. 0006-4971/96/8709-0135$3.00/0 crease of intracellular Ca2+ concentration stimulated by these aggregation inducers. A02131-1 was shown t o increase the cAMP and cGMP levels in platelets and the extent was found t o be dependent on concentration as well as time. A02131-1 increased the cAMP level much more slowly than the cGMP level. Activities of adenylate cyclase, guanylate cyclase, and PDEs (type I and 111) were not altered by A02131-1. However, the activity of cGMP-specific PDE (type VI was inhibited by A02131-1. The antiplatelet aggregation activity and the effect on raising cAMP level of A02131-1 were both potentiated by prostaglandin E, (PGE,). In the mouse tail bleeding test, A02131-1 was clearly shown t o be more effective than dipyridamole in prolonging the tail bleeding time of conscious mice. These data indicate that A02131-1 is a cGMP-specific PDE (type V) inhibitor in human platelets. 0 1996 by The American Society of Hematology.
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cyclin (PGI2)" or soluble guanylate cyclase by nitric oxide (NO)" blocks platelet aggregation and disaggregates preformed platelet aggregates as well. Both CAMP and cGMP have been assumed to mediate the antiplatelet effect by stimulating the phosphorylation of several protein substrates by CAMPIC AMP-dependent protein kinase (PKA) or cGMP/ cGMP-dependent protein kinase (PKG), respectively. More recently, Walter et a1'"'4 purified a 46/50 kD platelet protein termed vasodilator-stimulated phosphoprotein (VASP) and demonstrated the stoichiometric phosphorylation of VASP by both PKA and PKG in intact human platelets; and the stoichiometric phosphorylation of VASP by the two was closely correlated with their inhibition on platelet activation.
The signal transduction pathways of platelet affected by both cAMPPKA and cGMPPKG will result in the inhibition of platelet activation, most likely because of the inhibition of a series of agonist-induced events such as phosphoinositide breakdown, calcium mobilization, calcium influx, and subsequent Ca'+-/protein kinase C-mediated protein phosphorylation."~17 Intracellular concentrations of CAMP or cGMP are determined by their rate of formation, via agonist-induced stimulation of adenylate cyclase or guanylate cyclase, and hydrolysis by a related group of phosphodiesterases (PDEs). Multiple PDE isoforms have been characterized on their substrate specificity, their modulation by calmodulin or by cGMP, their pharmacological responses to drugs, and their primary sequence. Beavo and Reifsnyder" recently proposed to classify PDE isozymes into five major families called PDEs I, 11,111, IV, and V. PDEs I, 11, and 111 use both CAMP and cGMP as substrates; IV is CAMP-specific and V is cGMP-specific. Human platelets have been reported to contain three species of PDE isozymes, I, 111, and V."." Inhibitors of PDEs 111 and V have been described to prevent the aggregation of platelets in response to a variety of physiological inducers. '92' 22 Theoretically, antithrombotics should inhibit platelet aggregation without causing relaxation of the vascular smooth muscle.l"'' Unlike PDE 111 inhibitors, compounds that inhibit PDE V are relatively weak vasodilators. " Recently, in a large scale screening test, we found that A02 I3 1 -1, a chemically synthesized pyrazole compound,
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For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From possessed an antiplatelet aggregation activity. To elucidate the mechanism of its antiplatelet aggregation activity, a series of experiments were performed. The results reported here indicate that it is a novel inhibitor of cGMP-specific human PDE (type V). (Fig I) was chemically synthesized as described by Yoshina and Kuo.'~ Collagen (type I, bovine Achilles tendon, Sigma, St Louis, MO) was homogenized in acetic acid (25 mmoUL) and stored (1 mg/mL) at -70°C until use. Platelet-activating factor (PAF, I-o-akyl-2-acetyl-sn-glycero-3-phosphocholine, Sigma) was dissolved in chloroform and diluted in 0.1% bovine serum albumin (BSA)-saline solution immediately before use. All radioactive materials, my0-[2-~H]inositol, [a-32P]adenosine triphosphate (ATP), [a-32P]guanosine triphosphate (GTP), C3H]cAMP, and ['HIcGMP, and inositol 1,4,5-trisphosphate (IP,) radioimmunoassay kit were purchased from Amersham (Buckinghamshire, UK). Thromboxane B2 (TXB,), prostaglandin Dz (PGD,), CAMP, and cGMP enzyme immunoassay kits were obtained from Cayman Chemical Co (Ann Arbor, MI). Protein assay kit and neutral alumina were obtained from Bio-Rad (Richmond, CA). Unless otherwise noted, all other chemicals used in this investigation were purchased from Sigma.
MATERIALS AND METHODS

Materials
Blood was obtained from healthy volunteers who had not taken any drug in the past 10 days, and mixed 1:lO (voUvol) with 109 mmoUL of trisodium citrate (citrated blood). Platelet-rich plasma (PRP) was prepared by centrifugation of the blood at l50g for 10 minutes. Washed platelets (WP) were prepared from citrated PRP according to the procedure de~cribed.2~ Briefly, PRP was added with prostaglandin El (WE,, 0.5 pmoUL) and heparin (6.4 U/mL), incubated for 10 minutes at 37°C and centrifuged at 500g for 10 minutes. The platelet pellet was suspended in 5 mL of Tyrode's solution (mmolk NaCl 136.8, KCI 2.8, NaHC03 11.9, MgCl, 2.1, NaH2P04 0.33, and glucose 11.2), and then potato apyrase (Grade V, 1 U/mL), PGEl (0.5 pmoUL), indomethacin (1 pmoU L), and heparin (6.4 U/mL) were added. The mixture was incubated for 10 minutes at 37°C and wash4 3 times with Tyrode's solution. Finally, the platelets were suspended in Tyrode's solution containing BSA (0.35%) and CaCl, (1.0 mmoUL). The platelets in PRP or WP were counted by Hemalaser 2 (Sebia, Molineaux, France) and adjusted to a concentration of 3 X IO8 plateletdmL. For the measurement of aggregation, WP were supplemented with 100 pg/mL of fibrinogen.
The effect of A02131-
Blood preparations.
Platelet aggregation and release ofATP.
1 and other drugs on aggregation induced by arachidonic acid (AA), collagen, U46619 (9,l l-dideoxymethanoepoxy-9a,l la-PGFh), PAF, adenosine diphosphate (ADP), and A23187 was tested in citrated PRP or WP by turbidimetry as described by O'Brien.2s The bioluminescence methodz was used to detect the release of ATP from platelets. Aggregation of platelet and release of ATP were simultaneously measured in a Lumi-aggregometer (Chrono-Log Co, Havertown, PA) connected to two dual-channel recorders. For this, platelet preparation was stirred at 1,200 rpm. To assess the effect of inhibitors, platelets were incubated with the inhibitor for 3 minutes and quantitatively examined aggregation by measuring the maximal increase in light transmission 6 minutes after the addition of the inducer. Calibration was made with platelet-poor plasma when using PRP and with Tyrode's solution when using WP. To minimize the effect of dimethylsulphoxide (DMSO), the solvent, on aggregation, the final concentration of DMSO was fixed at 0.5% (voUvol) . The threshold activating concentration (TAC) of these inducers was defined as the minimal amount needed to give full, irreversible platelet aggregation (more than 60% light transmission) within 2 to 3 minutes. IC, is the concentration of the inhibitor that suppressed the agonist-induced aggregation by 50%.
After incubation of WP with the inducer for 6 minutes, EDTA (2 mmoUL) and indomethacin (50 pmoUL) were added to halt the formation of TXB2 and PGD,. The mixture was centrifuged (Eppendorf microcentrifuge, Model 5415C, Hamburg, Germany) for 2 minutes, and the TXB2 and PGD2 in the supernatant were assayed by enzyme immunoassay.
WP (500 pL, IO9 platelets/mL) prepared as described were incubated with 0.5% DMSO, or AO2131-1 at 37°C for 3 minutes and then added with the aggregation inducers. The reaction was terminated by the addition of 100 pL of ice-cold perchloric acid (20%) followed by 20 minutes incubation in an ice bath.
The mixture was centrifuged at 2,OOOg for 15 minutes at 4"C, the supernatant was collected and its pH was adjusted to 7.5 with a 10 N KOH solution. The KCIO, formed was allowed to precipitate for 30 minutes at 4°C and sedimented at 2, OOOg for 15 minutes at 4°C. The amount of IP3 in the supernatant was determined by radioimmunoassay.
The method of Pollock and Rink" was followed. PRP (3 X 10' platelets/mL) were incubated with fura-2-acetoxymethyl ester (fura-UAM, 5 pmoUL) at 37°C for 45 minutes and centrifuged at 500g. The pellet was washed with Tyrode's solution containing 1 mmoUL EDTA, and then resuspended in Tyrode's solution containing 1 mmoVL CaZ+. Fluorescence (Ex 340 nm, Em 500 nm) was measured with a Jasco Fluorescence Spectrophotometer (CAF 110, Jasco, Japan) at 37°C. At the end of the experiment, the cells were treated with 0.1 % Triton X-100 (Sigma), followed with 10 mmoUL of EGTA to obtain the maximal and minimal fluorescence, respectively. Intracellular Ca" concentration ([Ca2+Ii) was calculated from the fluorescence measured using 224 nmoUL as the Ca2+-fura-2 dissociation constant.28
The method of Kamiguian et dZ9 was employed. WP were w m e d at 37°C for 1 minute in an aggregometer with stirring at 1,200 rpm. The drugs, A02131-1, PGEl, dipyridamole, sodium nitroprusside, or 3-isobutyl-I-methylxanthine (IBMX) was then added and incubated for various lengths of time. The reaction was stopped by adding 10 mmoUL EDTA followed immediately by boiling for 5 minutes. On cooling to 4"C, precipitated protein was collected by centrifugation (Eppendorf, Model 5415 C). The supernatant was assayed for CAMP and cGMP by enzyme immunoassay. Concentrations of platelet CAMP and cGMP in WP were corrected for the contribution of extracellular nucleotides. WP were stored at -40°C until homogenization and chromatography. All subsequent procedures were per-TXB, and PGD, assay.
Assay of ZP3 content.
Measurement of intracellular Ca2+ in platelets.
Assay of platelet CAMP and cGMP.
Purz$cation of PDEs.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From formed at 4°C. WP (1 1.5 mL) were thawed on ice and homogenized in 35 mL of buffer (20 mmoVL Tris-HC1,5 mmoVL 2-mercaptoethanol, 2 mmoVL benzamidine, 2 mmoVL EDTA, and 50 mmoVL sodium acetate, pH 6.5) in a Polytron homogenizer for IO seconds. The homogenate (40 mL) was centrifuged for 20 minutes at 25,000g and the supematant applied to the DEAE-Sepharose CL-6B column (17 X 1.5 cm) (Pharmacia Biotech, Uppsala, Sweden) that had been pre-equilibrated with 170 mL homogenization buffer. A flow rate of 80 mLih was used throughout the ion-exchange chromatography procedure.'" The PDEs were eluted with a linear 400 mL, 50 to 1,OOO mmoK sodium acetate gradient. Fractions, 7.5 mL each, were collected and stored at 4°C until assay for PDE activities.
PDEs activity was determined according to Wells et al." The enzyme (1 mg/mL, 0.1 mL) was incubated with Tris-HC1 (0.2 mL) at 37°C for 5 minutes, and then 0.1 mL CAMP (final concentration 1 pmol/L containing 0.1 pCi ['HI-CAMP, with 1 mmoVL EGTA or 10 j"VL CaZf and 20 nmol/L calmodulin) or cGMP (final concentration 1 pmoVL containing 0.1 pCi ['HIcGMP, with 1 mmoVL EGTA) was added. After 30 minutes at 37"C, the sample was heated to 100°C for 1 minute then cooled. Ophiophagus hannah snake venom (1 mg/mL, 0.1 mL) was then added and incubated at 25°C for 30 minutes for the conversion of the 5'-AMP or 5'-GMP to the uncharged nucleoside, adenosine or guanosine, respectively. An ion-exchange resin slurry (1.0 mL Dowex-l, 100 to 200 mesh) was added to adsorb all unconverted cAMP and cGMP and centrifuged. A sample of 0.5 mL of the supematant was taken for the determination of ' H counts in a liquid scintillation counter.
WP, prepared as previously described, were resuspended in Tris-HC1 buffer (50 mmoVL, pH 7.4). The platelets were sonicated in ice for 10 seconds each time for 4 to 6 times with setting 5 (Vibra cell, Sonics and Materials Inc, Danbury, CT) and centrifuged at 39,OOOg at 4°C for 20 minutes. The supematant was used as a source of soluble guanylate cyclase. The pellet (platelet membrane) was washed twice with the same Tris-HCI buffer. Protein content was determined with a protein assay kit and adjusted to 1 mg/mL concentration. Guanylate cyclase activity was determined by the method described by Gerzer et ai. Platelet membrane fraction prepared as described and was resuspended in Tris-HC1 buffer containing 5 mmol/L EDTA. Adenylate cyclase activity was measured as described by Insel et al.14 The membrane fraction (20 pL) was added into a final volume of 60 pL of a reaction mixture consisting of 50 mmolk Tris-HC1, pH 7.4, 2.6 mmoVL EDTA, 13 m o V L MgCI,, 25 mmom creatine phosphate, 1 mglmL creatine phosphokinase, 1 mmol/L CAMP, 0.5 mmoVL ATP (containing 1 X IO6 cpm [a-"PIATP), and others as indicated in the text. The reaction was initiated by adding platelet protein and allowed to proceed at 30°C for 20 minutes. The reaction was terminated by adding 0.2 mL 0.5 N HCl and the mixture was boiled for 6 minutes. After cooling in an ice bath, imidazole (1 mmom, 200 pL) was added. ATP and cAMP were separated on neutral alumina" and the radioactive count (["PICAMP) was determined with a liquid scintillation counter.
Assay of PDEs activities.
Guanylate cyclase assay.
Adenylate cyclase assay.
Tail bleeding time in conscious mice. Thirty minutes after the intraperitoneal administration of DMSO (2.5 pL/g), A021 3 1 -1, dipyridamole, or indomethacin, the tail of the mouse (Balbk, male, 20 g) was transected at 2 mm from the tip and 1.5 cm of the distal portion was vertically immersed in saline at 37°C. The bleeding time was measured as described by Homstra et a1. 15 Results were expressed as means 2 SEM. The standard Student's t-test was used. P values less than .OS were considered statistically significant.
Statistical analysis.
RESULTS
Effect of A02131 -I on aggregation, disaggregation, and release of ATP. In human PRP, the maximal changes in light transmission observed at the TAC of AA (10 pmol/L), collagen (2 pg/mL), U46619 (2 pmoVL), PAF (30 nmol/L), ADP (5 pmoVL), and A23187 (5 pmol/L) were 68 t 4%, 78 t 3%, 80 5 4%, 63 t 7%, 69 t 3%, and 68 5 5%, respectively, which were achieved within 2 to 3 minutes. A02131-1 inhibited these aggregations and the degree of inhibition was proportional to its concentration. Figure 2A shows the inhibition against collagen-induced aggregation as a function of the concentration of A02131-1. The inhibition increased linearly up to 30 pmol/L with an IC,, of 3.7 t 1.2 pmoVL. Similar concentration-inhibition relationship could be observed with the other aggregation inducers, of which ICso are listed in Table 1 . The aggregation induced by AA, collagen, and U46619 was much more readily inhibited than that induced by the other three. A similar inhibition of aggregation was observed in WP as shown in Table 1 , where the aggregation by AA, collagen, and U46619 was again shown to be more readily suppressed as seen from the IC5,, values. In addition, the aggregation in WP induced by these inducers was completely inhibited by dipyridamole (100 pmoVL) (PDE V inhibitor), PGE, (10 bmol/L), or sodium nitroprusside (100 pmoVL) (n = 6).
As previously described, the inhibitory effect of A021 3 1-1 was dependent on the concentration, but independent of time, because the inhibition in WP observed with 3 pmol/L A02131-I in 3 minutes did not increase much after 30 minutes further incubation. On the other hand, the inhibitory effect was reversible: when WP after incubation with 30 pmol/L of A02131-1 for 30 minutes at room temperature were centrifuged, washed to remove the inhibitor, resuspended in fresh Tyrode's solution, and then treated with the inducers, the WP were again aggregated (data not shown). A02131-1 was also found to inhibit the binding of 1251-fibrinogen to ADP-stimulated platelets with an ICso similar to that for the inhibition of ADP-stimulated aggregation. A0213 1-1, however, was unable to suppress fibrinogen-induced aggregation of elastase-treated platelets (1.25 U/lOR platelets) (data not shown).
A02 13 1-1, at the concentration of 30 pmol/L, could also effectively disaggregate the preformed platelet aggregate caused by the inducers. As shown in Fig 3 where collagen and ADP were used respectively, as soon as A0213 1-1 was added into WP with fibrinogen, where the aggregation had been induced for 3 minutes, disaggregation occurred rapidly and extensively. In contrast, the addition of DMSO did not affect the aggregate. Disaggregation could also be seen, Experimental procedures were described in Materials and Methods. In PRP, the TAC was: 10 pmol/L for AA, 2 pg/mL collagen, 2 pmol/L U46619, 30 nmol/L PAF, 5 pmol/L ADP, and 5 pmol/L A23187. In WP, the TAC was the same as in PRP except 5 pmol/L for AA and 2 pmol/ L for ADP. Values are presented as means t SEM (n = 6).
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though less potently, with dipyridamole and sodium nitroprusside.
The inducers were also known to release ATP from platelets, and this release could also be inhibited by A02 13 1 -I. The inhibitory effect was also proportional to the concentration and corresponded to its ability to inhibit the inducer's ability to aggregate platelets. Fig 2C shows its inhibitory effect as a function of concentration on the release of ATP induced by collagen. As in the inhibition of aggregation, the inhibition of ATP release increased steadily as the concentration of AO2131-1 increased logarithmically. However, even when the antagonists, A02131-1, dipyridamole, PGE, , and sodium nitroprusside, completely blocked the aggregation and the release of ATP induced by the inducers, they did not suppress the ability of the inducers to change the shape of platelets (data not shown).
Effect of A02131-I on the formation of platelet TXB2 and PGD2. The amount of TXB2 in resting WP was 1.7 -+ 0.5 ng/3 X lo8 platelets. All the inducers except U46619 markedly increased the amount of TXB2 after incubation for 6 minutes. As shown in Table 2 , A02131-1 inhibited the TXB2 formation stimulated by collagen, PAF, ADP, and A23187 and the inhibition was proportional to the A02131-1 concentration used. However, it did not inhibit the TXB2 formation by AA even at the concentration of 30 pmol/L that inhibited more than 80% of the aggregation induced by AA. When the concentration of A021 3 1 -1 was increased to 60 pmoVL that completely blocked the AA-induced platelet aggregation, the AA-induced TXBz formation was only partially suppressed (Table 2) . Similar effects, including the ineffectiveness on the TXB2 formation that was induced by AA, could be seen with WE,, dipyridamole, and sodium nitroprusside (Table 2 ). In contrast, indomethacin (1 pmoVL) and imidazole (1 mmoVL) greatly inhibited the AA-induced TXB2 formation (Table 2) .
AA also increased the amount of PGD2 in platelets. The amount of PGD2 in resting platelets was 0.92 ? 0.01 ng/3 X lo8 platelets, which could be increased to 14.50 2 0.20 ng/3 X IO8 platelets ir. :he presence of 5 pmoVL AA. This PGD2 formation caused by AA was unaffected by the presFor personal use only. on September 14, 2017. by guest www.bloodjournal.org From and cGMP, and therefore, the effect of A0213 1-1 on the mation but with a slower rate, reaching a peak of 4.9 5 0.5 amount of these two was checked. The resting WP were pmoVlO' platelets within 30 seconds. A02131-1 (100 ymoll determined to contain 2.9 5 0.3 pmol/lO' platelets for cAMP L), PGE, (10 ymoVL), and sodium nitroprusside (100 /.mol/ and 1.6 t 0.2 for cGMP. The kinetic change in the amount L), at concentrations that markedly inhibited platelet aggreof these two was first examined using 1 0 0 ymoVL A02131-gation, substantially suppressed the IPS formation caused by 1. As shown in Fig 6A, after the addition of A0213 1-1, little these four inducers (Fig 4) . changes could be observed within 12 seconds for cGMP; its 3). action of AA, PAF, collagen, U46619, and A23187 in fura- Effect of A02131-I on platelet adenylate cyclase and guanylare cyclase activities. These enzymes produced the two cyclic nucleotides, cAMP and cGMP, and therefore whether or not A02 13 I -I affected the activities of these two enzymes was examined. The adenylate cyclase activity in resting WP was measured to be 7.1 ? 0.9 pmol cAMP formedmg proteinlminute. The addition of A02131-1 at 100 pmol/L did not affect the platelet adenylate cyclase activity, whereas both PGE, ( I pmol/L) and forskolin ( I O pnol/L) increased the activity to 57.6 5 4.0 and 88.6 ? 8.1 pmol cAMP formed mg proteinhinute, respectively (Table 4) .
The guanylate cyclase activity was checked in two fractions: platelet particulate and the soluble fraction that, when unperturbed, were found to have the activities of 18.6 ? 6.3 and 10.4 ? 3.3 pmol cGMP formedhg proteinhinute, respectively. A02 13 1 -1 ( 100 pnol/L) did not affect either fraction's activity, whereas sodium nitroprusside (IO and 100 pmol/L) increased the activity of the soluble fraction (Table 4) .
Effect qf A02131-I on platelet PDEs activities. The amount of cAMP and cGMP would also be affected by the activity of PDEs, and therefore, the effect of A02 13 1 -1 on the PDEs activities was checked. When platelet homogenate was fractionated by DEAE-Sepharose chromatography, three major peaks (fractions) of PDE activity were obtained. The first peak showed a low Km ( of PDE I and I11 in platelets. However, cGMP-specific PDE V activity was inhibited by both A021 3 1 -1 and dipyridamole and the inhibition was proportional to the concentration ( Fig  7B) .
A number of tests were performed to see the interaction of A02131-1 with the agents that also inhibit platelet aggregation. PGEl was one of such agents, but at a low concentration of 0.1 pmoVL, it showed only 4 2 2% inhibition of aggregation. On the other hand, when combined with 0.3 pmoVL of A02131-1, which at that concentration produced 16 2 3% inhibition, the inhibition of aggregation sharply increased to 72 rt 6%. In the presence of 200 pmoVL 2'3'-dideoxyadenosine (DDA, an adenylate cyclase inhibitor), the increase in CAMP and the synergistical inhibition of platelet activity caused by AO2131-1 (0.3 pmoVL) and PGEl (0.1 pmoVL) were both suppressed (data not shown). A synergistic effect was also observed with a mixture of 0.3 pmoVL AO2131-1 and 0.1 pmoVL sodium nitroprusside, the latter alone, at this Synergistic effect of A02131 -I and other agents.
concentration, inhibited only 5 ? 2% of collagen-induced platelet aggregation: the antiaggregatory effect of A02 13 1 -1 was seen to increase from 15 +-2% to 67 ? 7%.
Synergistic effect on the level of CAMP was also observed by some agents. As seen in Table 5 , the agents, IBMX, sodium nitroprusside, dipyridamole, A02013-1, cilostamide (a PDE I11 inhibitor), and PGEl, all increased the platelet CAMP level. Synergistic increase in CAMP could not be observed when AO2131-1 was mixed with these agents except for PGE1. As seen in Table 5 , synergistic effect on the level of CAMP was clearly seen when PGE, was combined, respectively, with the other agents. However, when cilostamide or sodium nitroprusside was added to the mixture of PGEl and A02131-1, the synergistic effect of AO2131-1 already seen was not greatly enhanced further ( Table 5) . The greatest effect, more than 12-fold, was seen when PGE, was incubated with IBMX. As to the level of cGMP, PGEl did not further increase the production of cGMP caused by A02131-1 (data not shown).
One of the roles of platelet aggregation is to stop bleeding. Therefore, the effect of A02131-1 on the bleeding time was checked using the mouse tail bleeding system. The tail bleeding time of untreated mice was measured to be 60.3 t 5.4 seconds (n = 10). DMSO (2.5 pL/g) alone showed little effect (69.7 +. 7.6 seconds, n = 10). Among the three inhibitors tested, indomethacin (10 mgkg) showed the longest bleeding time, substantially longer than A02131-1 even at 10 mgkg. Dipyridamole (10 mgkg) showed the shortest among the three (Table 6 ).
Effect ofA02131-I on the tail bleeding time of mice.
DISCUSSION
As clearly shown here AO2131-1 inhibits as well as disaggregates platelet aggregation by inhibiting the actions of several aggregation inducers used here. Platelet aggregation can be inhibited when the binding of fibrinogen to its receptor, glycoprotein IIb-IIIa, is somehow interfered. A021 3 1-1, however, does not seem to be a fibrinogen receptor antago- nist, because it does not inhibit the fibrinogen-induced aggregation of platelets that are treated with elastase. Platelet aggregation is a result of complex signal transduction cascade reactions brought about by stimulants. One of the components in the cascade is TXAz that is an important mediator of platelet aggregation and release of ATP.% TXBz is a stable metabolite of T U 2 . Some aggregation inducers such as collagen, PAF, ADP, and A23187 were shown to stimulate the formation of TXB2, thus suggesting the production of TXA2. AO2131-1, however, inhibits this T X B 2 forming action of these inducers. On the other hand, A02131-1 does not inhibit the production of TXBz stimulated by AA, although 80% of platelet aggregation induced by the extemal AA are inhibited. Furthermore, A02131-1 is ineffective in inhibiting the AA's action on the E D z formation. These results suggest Incubation and termination were described in Materiels and Methods. CAMP content in platelets was determined by enzyme immunoassay and expressed as means 2 SEM (n = 4-7).
that A02131-1 inhibits the production of intracellular T U 2 and acts on a step before the cyclooxygenase step. In other reaction pathways, phosphoinositide breakdown is an important reaction for agonist-induced platelet acti~ation.~'.~~ This breakdown generates two active products, diacylglycerol and IP3, and the latter triggers intracellular Ca2+ mobilization and subsequent activation of phospholipase Az that is a rate limiting enzyme for the generation of AA. The increase in IP3 and [Ca2+li is stimulated by the inducers such as AA, PAF, collagen, U46619, andA23187. A02131-1 also inhibits these inducers and suppresses the increase Of IP, and [Caz'li.
Therefore, the suppression of the TXBz formation by A02 13 1 -1 against these inducers may be a result of A021 3 1 -1 inhibiting the breakdown of phosphoinositide, which is affected by the level of CAMP and cGW.15-17 As previously shown, AO2131-1 raises the level of these two nucleotides (Fig 6) .
The elevation of CAMP and/or cGMP levels inhibits platelet aggregation as well as most other platelet responses including the release of ATP and the rise of [Ca2']i.w The PDE V inhibitors have a potential for the use in the treatment of arterial thrombosis?6 Dipyridamole, a PDE V inhibitor, has been extensively used as an antithrombotic agent in clinical applications. A02131-1 is also a PDE V inhibitor, as previously shown, and more potent than dipyridamole in inhibiting platelet functions in vitro and in vivo, such as, when applied intraperitoneally to the mouse, the tail bleeding time is substantially longer than the prolonged bleeding time shown by dipyridamole (Table 6 ). Thus AO2131-1 could b e an antithrombotic agent useful for the prevention or treatment of thrombosis.
